(NASDAQ: PSTV) Plus Therapeutics's forecast annual revenue growth rate of 13.89% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Plus Therapeutics's revenue in 2024 is $4,913,000.On average, 1 Wall Street analysts forecast PSTV's revenue for 2024 to be $40,323,453, with the lowest PSTV revenue forecast at $40,323,453, and the highest PSTV revenue forecast at $40,323,453. On average, 1 Wall Street analysts forecast PSTV's revenue for 2025 to be $33,524,483, with the lowest PSTV revenue forecast at $33,524,483, and the highest PSTV revenue forecast at $33,524,483.
In 2027, PSTV is forecast to generate $33,567,244 in revenue, with the lowest revenue forecast at $33,567,244 and the highest revenue forecast at $33,567,244.